Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc. Buprenorphine extended-release implant (Probuphine; Braeburn Pharmaceuticals Inc.) for opioid use disorder. Lansdale: HAYES, Inc. Healthcare Technology Brief Publication. 2017 Authors' conclusions Patients with opioid use disorder may benefit from medication-assisted treatments that include a combination of medication and behavioral therapy.
Technology Description:
Probuphine is an implantable system containing buprenorphine hydrochloride, which is an opioid partial agonist drug intended to ease symptoms of withdrawal and opioid cravings. The implantable system allows for
extended release of the drug.
Patient Population:
Probuphine is intended for treatment of opioid dependence in patients who have achieved and maintained low-to-moderate daily doses of sublingual buprenorphine.
Clinical Alternatives:
Alternatives to Probuphine that are appropriate for outpatient use include sublingual or oral buprenorphine, sublingual buprenorphine-naloxone, oral methadone, and oral naltrexone Indexing Status Subject indexing assigned by CRD MeSH Buprenorphine; Humans; Narcotic Antagonists; Opioid-Related Disorders; Pharmaceutical Preparations Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence HAYES, Inc., 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218 Email: hayesinfo@hayesinc.com AccessionNumber 32018000010 Date abstract record published 30/01/2018 |